Completed Trials – No Longer Enrolling

Ocrelizumab for Relapsing and Active Multiple Sclerosis (OPERA, WA21092)

Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate
The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis

Closed 12/21/12, Screened 17, Enrolled 16

Dalfampridine after Optic Neuritis to Improve Visual Function in Multiple Sclerosis (IIS)

Closed 1/2/14 , Screened 53, Enrolled 45, Retained 44.

LINGO for Relapsing and Active Multiple Sclerosis (SYNERGY, 215MS201)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of Multiple Sclerosis When Used Concurrently with Avonex® (215MS201)

Closed 4/10/14, Screened 3, Enrolled 3.

Teriflunomide (Aubagio®) for Relapsing Multiple Sclerosis (TERI-PRO, LPS13567)

A Prospective, Single-Arm, Clinical Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

Closed 4/15/14, Screened 20, Enrolled 19.

Pegylated Interferon for Relapsing Multiple Sclerosis (ALLOW, 105MS303)

An Open-Label, Two-Arm, Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning from Current Interferon Beta Therapies to BIIB017 (215MS301, ALLOW)

Closed 10/13/14, Screened 23, Enrolled 17

Efficacy, Safety, and Tolerability of Plovamer Acetate

Closed. Screened 2, Enrolled 1